Previous close | 1.1200 |
YTD return | N/A |
Expense ratio (net) | N/A |
Category | N/A |
Last cap gain | N/A |
Morningstar rating | N/A |
Morningstar risk rating | N/A |
Sustainability rating | N/A |
Net assets | N/A |
Beta (5Y monthly) | N/A |
Yield | N/A |
5y average return | N/A |
Holdings turnover | N/A |
Last dividend | N/A |
Average for category | N/A |
Inception date | N/A |
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY), today announces that the company has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for OX124, a high-dose naloxone rescue medication in development for opioid overdose. The NDA was submitted to the FDA on September 18, 2023. The CRL indicates the need for an additional Human Factors (HF) study, which is in line with previous communication. Furthermore, additional techn
Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) announces that it has received a Gold Sustainability Rating by EcoVadis, one of the world´s most trusted provider of business sustainability ratings. The highly revered award places the company in the top 5 percent of all 70,000 businesses worldwide that are reviewed by EcoVadis each year.